Minerva Neurosciences, Inc. (NERV)
2.32
+0.08
(+3.57%)
USD |
NASDAQ |
Oct 30, 16:00
2.30
-0.02
(-0.86%)
After-Hours: 20:00
Minerva Neurosciences Free Cash Flow : -26.17M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -26.17M |
| March 31, 2026 | -14.87M |
| December 31, 2025 | -13.51M |
| September 30, 2025 | -14.20M |
| June 30, 2025 | -15.63M |
| March 31, 2025 | -17.53M |
| December 31, 2024 | -19.55M |
| September 30, 2024 | -20.38M |
| June 30, 2024 | -20.83M |
| March 31, 2024 | -20.76M |
| December 31, 2023 | -14.78M |
| September 30, 2023 | -12.92M |
| June 30, 2023 | -17.65M |
| March 31, 2023 | -18.97M |
| December 31, 2022 | -24.66M |
| September 30, 2022 | -25.37M |
| June 30, 2022 | -24.46M |
| March 31, 2022 | -25.19M |
| December 31, 2021 | -24.60M |
| September 30, 2021 | -26.93M |
| June 30, 2021 | -28.17M |
| March 31, 2021 | -29.84M |
| December 31, 2020 | -33.82M |
| September 30, 2020 | -40.84M |
| June 30, 2020 | -40.49M |
| Date | Value |
|---|---|
| March 31, 2020 | -43.03M |
| December 31, 2019 | -43.43M |
| September 30, 2019 | -39.05M |
| June 30, 2019 | -39.51M |
| March 31, 2019 | -40.61M |
| December 31, 2018 | -41.94M |
| September 30, 2018 | -41.11M |
| June 30, 2018 | -6.228M |
| March 31, 2018 | -1.847M |
| December 31, 2017 | 3.040M |
| September 30, 2017 | 3.077M |
| June 30, 2017 | -26.47M |
| March 31, 2017 | -25.68M |
| December 31, 2016 | -25.69M |
| September 30, 2016 | -23.36M |
| June 30, 2016 | -24.43M |
| March 31, 2016 | -25.41M |
| December 31, 2015 | -24.27M |
| September 30, 2015 | -22.68M |
| June 30, 2015 | -44.12M |
| March 31, 2015 | -39.63M |
| December 31, 2014 | -36.01M |
| September 30, 2014 | -32.19M |
| June 30, 2014 | -5.379M |
| March 31, 2014 | -3.224M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Heron Therapeutics, Inc. | -12.14M |
| Tonix Pharmaceuticals Holding Corp. | -160.40M |
| Karyopharm Therapeutics, Inc. | -65.35M |
| Corbus Pharmaceuticals Holdings, Inc. | -86.69M |
| Ocugen, Inc. | -61.02M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -13.34M |
| Cash from Investing (Quarterly) | -4.833M |
| Cash from Financing (Quarterly) | 10.17M |
| Free Cash Flow Per Share (Quarterly) | -0.1687 |
| Free Cash Flow to Equity (Quarterly) | -20.12M |
| Free Cash Flow to Firm (Quarterly) | -13.34M |
| Free Cash Flow Yield | -31.84% |